Pharmaceutical industry: latest news

Pharmaceutical industry features

Pharmaceutical industry news from aidsmap

More news

Pharmaceutical industry news selected from other sources

  • Treat pharma as a utility, and 10 other ways states can lower drug prices

    As prescription drug costs continue to squeeze state budgets, a group of state health policy makers is offering some novel — and also some familiar — suggestions for coping. These include regulating the pharmaceutical industry as a utility, allowing states to operate as pharmacy benefit managers and waiving some provisions of the Medicaid program.

    19 October 2016 | STAT
  • European regulator amends some Gilead hep C patent claims

    In a setback for Gilead Sciences, European regulators decided not to uphold all of its patent claims for the best-selling Sovaldi hepatitis C treatment, a move that could lead to generic versions of the medicine becoming available four years sooner than had been expected.

    06 October 2016 | STAT
  • CHMP Recommends for Approval Generic Version of Truvada

    At its September meeting, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended for approval a generic version of Truvada – Emtricitabine/Tenofovir disoproxil Zentiva (emtricitabine/tenofovir disoproxil) for the treatment of HIV infection.

    20 September 2016 | EATG
  • Behind Battle Over Drug Prices, Quiet Money From Big Pharma

    Is there a conflict of interest for hepatitis C advocates in accepting funds from pharmaceutical companies and representing the interests of patients when questions of drug pricing and access to treatment are being debated?

    19 September 2016 | Bloomberg
  • Janssen Submits Marketing Authorisation Application for Darunavir-Based Single Tablet Regimen for Treatment of HIV-1 to European Medicines Agency

    If approved, this tablet would be the first protease inhibitor-based STR option indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 infection in adults and adolescents. This new treatment would combine the protease inhibitor, darunavir (DRV, D, 800 mg), with the pharmacokinetic enhancer, cobicistat (COBI, C, 150 mg) and the nucleoside reverse transcriptase inhibitors emtricitabine (FTC, F, 200 mg) and tenofovir alafenamide (TAF 10 mg), in one single tablet.

    13 September 2016 | Janssen-Cilag press release
  • ContraVir Reports New CRV431 Data Highlighting Synergistic Activity with CMX157 Against Hepatitis B

    ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, today announced that it has taken a major step forward in its pursuit of a potentially curative combination therapy for chronic hepatitis B (HBV).

    12 September 2016 | ContraVir press release
  • Drug firm boss who raised price of HIV medicine trolls Hillary Clinton after collapse at 9/11 memorial service

    A 'hated' drug firm boss who raised the price of HIV medicine recorded a video of himself trolling Hillary Clinton after she collapsed at a 9/11 memorial service. Martin Shkreli shouted abuse at the politician as she left her daughter's apartment where she had been resting after suffering from pneumonia

    12 September 2016 |
  • WHO launches Target Regimen Profiles for TB treatment

    Aimed at the pharmaceutical industry, research institutions, product development partnerships and donors, the new profiles seek to guide the drug/regimen development process, enabling important drug and regimen features to respond to the needs of end-users, care providers and policymakers.

    08 September 2016 | World Health Organization
  • Letter to Gilead Sciences on attempts to remove generic sofosbuvir from Ukraine

    MSF is in the process of planning and beginning to deliver hepatitis C treatment to patients in Ukraine, a country suffering from the highest hepatitis C prevalence in the region - and which has one of the world’s highest rates of hepatitis C infection. The availability of multiple sources of new DAAs - and, in particular, sofosbuvir - is critical for treatment providers, including MSF, to manage a sustainable and affordable supply for medical operations.

    07 September 2016 | MSF
  • Doctors Without Borders urges Gilead to rethink its hepatitis C strategy in Ukraine

    The latest battle over access to medicines is taking place in Ukraine, where Doctors Without Borders is urging Gilead Sciences to drop a court action that, if successful, would prevent a generic version of the Sovaldi hepatitis C treatment from ...

    07 September 2016 | STAT
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap